Genelux Q1 EPS Cut by Brookline Capital Management

Genelux Co. (NASDAQ:GNLX - Free Report) - Equities research analysts at Brookline Capital Management decreased their Q1 2025 earnings estimates for shares of Genelux in a research note issued on Monday, March 31st. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings per share of ($0.23) for the quarter, down from their prior forecast of ($0.20). The consensus estimate for Genelux's current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Genelux's Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.21) EPS and FY2025 earnings at ($0.86) EPS.

Separately, HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Genelux in a report on Monday, March 31st. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $18.25.

Genelux Trading Up 1.6 %

NASDAQ GNLX traded up $0.04 on Thursday, hitting $2.20. The company's stock had a trading volume of 84,549 shares, compared to its average volume of 233,283. The firm has a market cap of $75.96 million, a P/E ratio of -2.36 and a beta of -0.36. Genelux has a 52-week low of $1.60 and a 52-week high of $5.89. The company's 50-day simple moving average is $3.96 and its 200 day simple moving average is $3.10.

Genelux (NASDAQ:GNLX - Get Free Report) last posted its earnings results on Friday, March 28th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.09).

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in GNLX. Virtu Financial LLC purchased a new position in shares of Genelux in the 4th quarter valued at approximately $25,000. Apollon Wealth Management LLC raised its holdings in Genelux by 20.4% in the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company's stock worth $40,000 after purchasing an additional 2,857 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Genelux during the fourth quarter valued at $41,000. D.A. Davidson & CO. bought a new stake in shares of Genelux during the 4th quarter valued at $51,000. Finally, XTX Topco Ltd purchased a new stake in shares of Genelux in the 3rd quarter worth about $59,000. Hedge funds and other institutional investors own 37.33% of the company's stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.